Abstract
You have chosen to resist to your instinct of not reading this chapter about regulations in fat grafting—and rightfully! Because only detailed knowledge about regulations will allow you to successfully implement regenerative treatments in your practice: it will enable you to lead informed discussions with your local health authorities - because they will contact you and require detailed information about what you do-, to communicate properly with patients about regenerative surgery and to educate the public about stem cells, their indications, risks and benefits. Unlike other physicians who are just pretending to perform ‘some stem cell therapy’, acting in compliance with regulations is a key for the true leaders in the field - and for being recognized as such.
Regenerative surgeons need to realize that regulation is paramount on every step of the way: from the clinical indication, the choice of harvesting techniques and processing devices, the selection of used cell types and its application up to the therapeutic objective and the patient communication in terms of promised effects.
Only through compliance with regulatory, medical and ethical standards it will be possible to maintain the partnership with the regulatory bodies and to fulfil the therapeutic promise of regenerative medicine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schwalie PC, Dong H, Zachara M, Russeil J, Alpern D, Akchiche N, Caprara C, Sun W, Schlaudraff K-U, Soldati G, Wolfrum C, Deplancke B. A stromal cell population that inhibits adipogenesis in mammalian fat depots. Nature. 2018;559(7712):103–8.
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products (ATMPs) and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Status as of July 25th 2019).
EudraLex: the rules governing medicinal products in the European Union Volume 4: good manufacturing practice: guidelines on good manufacturing practice specific to advanced therapy medicinal products (Status as of November 22nd 2017).
Regulation (EC) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Status as of May 27th 2014).
Directive 2004/23/EC of the European Parliament and of the Council of March 31st 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells (Status as of August 8th 2009).
European Norm EN ISO 22716:2007 (Status as of February 2008) Cosmetics—Good Manufacturing Practices (GMP) International Organization for Standardization (ISO).
Reflection paper of the EMA Committee for Advanced Therapies (CAT) on classification of Advanced Therapy Medicinal Products EMA/CAT/600280/2010 rev.1 (Status as of May 21st 2015).
Directive 2006/17/EC (status as of April 21st 2016) on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.
Directive 2006/86/EC (status as of October 24th 2006) of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells.
Directive 2009/120/EC (status as of September 14th 2009) of the European Parliament and of the Council amending Directive 2001/83/EC of the Community code relating to medicinal products for human use as regards advanced therapy medicinal products.
Swiss Federal Act No 810.21 on the Transplantation of Organs, Tissues and Cells (Transplantation Act) of 8 October 2004 (Status as of 1 January 2019).
Swiss Federal Act No 812.21 on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA) of December 2000 (Status as of January 1st 2020).
Swiss Federal Act No 810.211 on the Transplantation of human Organs, Tissues and Cells (Transplantation Act) of March 16th 2007 (Status as of November 15th 2017).
Swiss Federal Act No 817.023.31 on Cosmetic Products (VKos) of December 2016 (Status as of July 1st 2020).
Swiss Norm SN EN ISO 22716 (Edition: 2008-02) Cosmetics—Good Manufacturing Practices (GMP) based on Guidelines on Good Manufacturing Practices (ISO 22716:2007).
Djonova J. (Transplant unit at the swiss agency for therapeutic products, Swissmedic): the Swiss regulation of transplants and ATMPs. Oral communication at iCAST meeting 2019.
Kokai L, Sivak W, Schilling B, Karunamurthy A, Egro F, Schusterman M, Minteer D, Simon P, D’Amico R, Rubin JP. Clinical evaluation of an off-the-shelf allogeneic adipose matrix for soft tissue reconstruction. Plast Reconstr Surg Global Open. 2020;8(1):e2574.
Ren ML, Peng W, Yang ZL, Sun XJ, Zhang SC, Wang ZG, Zhang B. Allogeneic adipose-derived stem cells with low immunogenicity constructing tissue-engineered bone for repairing bone defects in pigs. Cell Transplant. 2012;21(12):2711–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Schlaudraff, KU. (2022). Fat Grafting, Tissue Banking, and Adipose Stem Cell Therapies: European Regulatory Status in 2021. In: Kalaaji, A. (eds) Plastic and Aesthetic Regenerative Surgery and Fat Grafting. Springer, Cham. https://doi.org/10.1007/978-3-030-77455-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-77455-4_12
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-77454-7
Online ISBN: 978-3-030-77455-4
eBook Packages: MedicineMedicine (R0)